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ABSTR ACT
BACKGROUND AND AIMS: Inflammatory bowel diseases (IBD) are frequently associated with altered liver function tests (LFTs). The causal rela-
tionship between abnormal LFTs and IBD is unclear. The aim of our study was to evaluate the prevalence and etiology of LFTs abnormalities and their 
association with clinical variables in a cohort of IBD patients followed up in a single center.
MATERIALS AND METHODS: A retrospective review was undertaken of all consecutive IBD in- and outpatients routinely followed up at a single 
referral center. Clinical and demographic parameters were recorded. Subjects were excluded if they had a previous diagnosis of chronic liver disease. LFT 
abnormality was defined as an increase in aspartate aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-
glutamyl transpeptidase (GGT), or total bilirubin.
RESULTS: A cohort of 335 patients (179 males, mean age 46.0 ± 15.6 years) was analyzed. Abnormal LFTs were detected in 70 patients (20.9%). In most 
cases, the alterations were mild and spontaneously returned to normal values in about 60% of patients. Patients with abnormal LFTs were less frequently 
on treatment with aminosalicylates (22.8 vs. 36.6%, P = 0.04). The most frequent cause for transient abnormal LFTs was drug-induced cholestasis (34.1%), 
whereas fatty liver was the most frequent cause of persistent liver damage (65.4%). A cholestatic pattern was found in 60.0% of patients and was mainly 
related to older age, longer duration of disease, and hypertension.
CONCLUSIONS: The prevalence of LFT abnormalities is relatively high in IBD patients, but the development of severe liver injury is exceptional. 
Moreover, most alterations of LFTs are mild and spontaneously return to normal values. Drug-induced hepatotoxicity and fatty liver are the most relevant 
causes of abnormal LFTs in patients with IBD.
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Hepatobiliary diseases constitute some of the most common 
extra-intestinal problems of inflammatory bowel diseases 
(IBD).1 Reported prevalence of liver and biliary tree illnesses 
in IBD ranges from  3% to more than  50%, depending on 
whether the definition of disease includes only definite con-
ditions, persistent or also transient elevation of hepatic bio-
chemistries.2,3  Elevation of liver function tests (LFTs) has 
been observed from  11  to  49% in IBD patients in different 
studies.4–6 A true estimation of the prevalence of altered LFTs 
in IBD patients is difficult to reach because different methods 
have been used for data collection, diagnostic criteria differ 
from one study to another, and patient selection has not been 
standardized.
Hepatobiliary diseases in IBD may be caused by an 
altered immune response and may also be linked to adverse 
reactions to drugs.1,7 The most common immunological dis-
order is primary sclerosing cholangitis (PSC). Autoimmune 
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within a period of three months and follow-up repeat LFTs 
were normal.
Patients who had abnormal LFTs repeat LFTs every 
three to six months. If the LFTs did not normalize, and the 
values were persistently abnormal, the  highest values of LFTs 
were taken into consideration. Patients with initial normal 
LFTs underwent follow-up only when they were on azathio-
prine (AZA), 6-mercaptopurine (MP), or MTX or when they 
had abnormal findings on abdominal imaging, such as hepa-
tosplenomegaly. All patients with abnormal LFTs underwent 
abdominal ultrasound (US) examination, virological tests 
to rule out hepatitis B and C infection, and laboratory tests 
including autoantibodies (antinuclear autoantibodies, anti-
smooth muscle autoantibodies, anti-liver/kidney autoanti-
bodies, and anti-mitochondrial autoantibodies). Patients with 
transient abnormal LFTs did not have a complete imaging and 
immunological evaluation. DILI was diagnosed if the LFTs 
increased after the recent use of a hepatotoxic  medication and 
the levels returned back to normal after the drug was stopped.
Statistical analysis. For continuous variables, the mean 
and standard deviation (SD) were calculated. For categorical 
variables, the frequency and corresponding percentages were 
provided. To explore univariate associations of categorical 
data distribution, chi-squared test or Fisher’s exact test was 
used, as appropriate. Continuous variables were compared 
by Student’s t-test. A P value less than 0.05 was considered 
statistically significant. Data statistical analyses were per-
formed using the Statistical Package for Social Science (SPSS) 
version 13.0 for Windows.
Results
A total of  376  IBD patients were identified from the data-
base. In all, 41 patients (10.9%) were excluded from the study 
for the following reasons:  19  (5.05%) patients because LFT 
abnormalities were related with definite chronic liver dis-
eases, either autoimmune (5  PSC,  2  AIH) or chronic viral 
hepatitis (11 HCV related, 1 HBV related), and 22 because of 
unavailable hepatic biochemistries. Subsequently, the records 
of  335  patients were accessible for the analysis. The study 
included  194  (57.9%) patients with CD and  141  (42.1%) 
with UC. According to Vienna classification, CD patients 
presented the following characteristics: age at diagnosis—
A1  below  40  years,  65.5% and A2  above  40  years,  34.5%, 
location—L1  ileal,  25.8%; L2  colonic,  10.3%; L3  ileoco-
lonic,  56.7%; and L4  upper,  7.2%, and behavior—B1  non-
stricturing, non-penetrating,  42.8%; B2  stricturing,  35.6%; 
and B3  penetrating,  14.9%,  6.7% had both stricturing and 
penetrating disease. In all,  30  patients (15.4%) had perianal 
involvement. Location distribution for UC patients was as 
follows: proctitis/proctosigmoiditis (14.2%), left-sided colitis 
(52.5%), and pancolitis (33.3%). Table 1 summarizes the differ-
ences between UC and CD patients. UC patients were slightly 
older (50.5  ±  15.8  vs.  42.6  ±  14.6  years) and had a  longer 
 duration of disease (5  years) than patients with CD 
hepatitis (AIH) has also been described, and an overlap 
 syndrome sharing features of PSC and AIH has been reported 
in some IBD patients.8,9 Apart from classical immunological 
liver diseases, other abnormalities are more often observed. 
Non-specific hepatomegaly is commonly reported in IBD and 
is strictly related to fatty liver. Fatty liver has been described 
in clinical studies in more than 30% of patients, and it does 
not seem to be related to sex and kinds of IBD.2 Also chole-
lithiasis is more frequent in IBD patients than in the general 
population.7 Drug-related hepatotoxicity (drug-induced liver 
injury, DILI) is a relevant cause of altered LFTs, in particular 
in patients receiving thiopurines.10 Methotrexate (MTX) and 
infliximab have also been reported to cause liver damage in 
IBD patients.11,12
In this study, we report the prevalence of LFT abnor-
malities in a cohort of IBD patients followed up in a single 
center. Furthermore, we evaluate the etiology and the risk fac-
tors associated with abnormal LFTs.
Patients and Methods
A retrospective review of the clinical records of the Gastroen-
terology Unit, at University of Palermo was undertaken. All 
charts were reviewed identifying IBD inpatient and outpa-
tient seen in the clinic between  2007  and  2009. The study 
was conducted after approval from the hospital ethical com-
mittee. Moreover, there was a waiver of the informed con-
sent. The diagnosis of IBD was established according to 
standard clinical, endoscopic, histological, and radiological 
 criteria.13 Disease features were defined using the Vienna clas-
sification,14 based on age at diagnosis, location, and behavior 
for Crohn’s disease (CD), the ECCO (European Crohn’s and 
Colitis  Organization) criteria,15 and the location and extension 
of the disease, for ulcerative colitis (UC). Patients in whom 
hepatic biochemistries were not obtained were excluded from 
the analysis. We also excluded patients with positive hepatitis B 
(HBV) or hepatitis C virus (HCV) markers and with previ-
ous diagnosis of chronic liver disease. Other analyses, such as 
hemochromatosis and Wilson’s disease screening, were per-
formed only by clinical judgment when needed. The  following 
data were collected from each patient at the time of the last 
follow-up visit: demographic characteristics (age,  gender, body 
weight, height), smoking habit, IBD type, disease duration, 
site of involvement and behavior, presence of extra-intestinal 
manifestations, past and current medications, and thorough 
medical history (including diabetes, hypertension, dyslipid-
emia, and obesity).
Abnormality of LFTs was defined as an increase in 
serum aminotransferases (alanine aminotransferase, ALT; 
aspartate aminotransferase, AST), alkaline phosphatase 
(ALP), gamma-glutamyl transpeptidase (GGT), or total bili-
rubin. The abnormal LFT pattern was characterized as fol-
lows: “cytolytic” type was defined as ALT/ALP ratio 5 and 
“cholestatic” type as ratio 2. The LFT abnormalities were 
considered transient if the liver enzymes returned to normal 
LFTs abnormalities in patients with IBD 
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Male 100 (51.5%) 79 (56.0%) 0.5
Female 94 (48.5%) 62 (44.0%)
Mean age (yrs) 42.6 ± 14.6 50.5 ± 15.8 0.001
Duration of disease (months)
1 year 24 (12.4%) 12 (8.5%) 0.001
1–5 years 84 (43.3%) 46 (32.6%)
5 years 86 (44.3%) 83 (58.9%)
extraintestinal manifestations 54 (27.8%) 15 (10.6%) 0.001
Previous surgery 54 (27.8%) 9 (6.4%) 0.3
Current smokers 61 (31.4%) 17 (12.0%) 0.001
Medical treatment#
•	 Only aminosalicylates* 59 (30.4%) 54 (38.3%) 0.2
•	 Any corticosteroids** 59 (30.4%) 55 (39.0%) 0.1
•	 Immunosuppressive agents*** 40 (20.6%) 26 (18.4%) 0.7
•	 TNF-antagonists**** 42 (21.6%) 9 (6.4%) 0.001
Obesity 23 (11.8%) 3 (2.1%) 0.001
diabetes 7 (3.6%) 17 (12.0%) 0.003
Hypertension 29 (14.9%) 18 (12.7%) 0.6
Hypercholesterolemia 13 (6.7%) 17 (12.0%) 0.09
Notes: #Some patients with more than one treatment. *Mesalazine, sulfasalazine; **Includes budesonide, prednisone, methylprednisolone; ***Azathioprine, 
6-mercaptopurine, methotrexate; ****Infliximab, adalimumab.
 
(P  0.001).  Significant differences were found in the propor-
tion of smokers (P   0.001), extra-intestinal manifestations 
(P   0.001), and obesity (P =  0.001) between CD and UC 
patients. Diabetes was more frequently found in UC patients 
(P =  0.003). The use of anti-Tumor Necrosis Factor (aTNF) 
alpha agents was significantly higher in patients with CD 
(P  0.001) as expected.
Abnormal LFTs were detected in  70  (20.9%) patients 
(44 males, mean age 48.1 ± 15.0), equally distributed among 
CD and UC (21.6 vs. 19.9%). A comparison of demographic 
and clinical features between the groups with normal and 
abnormal LFTs is shown in Table 2. On univariate analysis, 
there were no significant differences between the two cohorts 
as regard to gender, age, duration of disease, history of pre-
vious intestinal resection, extra-intestinal manifestation, and 
smoking. Patients with abnormal LFTs were less likely to 
be taking aminosalicylates than those with normal hepatic 
biochemistries (22.8 vs. 36.6%, P = 0.04). The use of other 
medications, such as corticosteroids, immunosuppressant, 
and TNF-antagonists, did not differ between the two groups. 
The increase in enzyme elevation was mild. In patients with 
abnormal LFTs, the median AST level was 41 U/L (inter-
quartile range [IQR] 24 U/L, normal 35 U/L), the median 
ALT level was  61  U/L (IQR  33  U/L, normal 41  U/L), 
the median GGT level was  76  U/L (IQR  82  U/L, nor-
mal  36  U/L), the median ALP level was  120  U/L 
(IQR 165 U/L, normal 104 U/L), and the median of total 
bilirubin was 0.75 mg/dL.
Persistent two-fold LFT elevation was found in 26 (37.1%) 
out of  70  patients (Table  3). These data were confirmed by 
subsequent biochemical control after three months since 
first detection. In the remaining patients, the enzyme eleva-
tion was transient, lasting for not more than three months. 
The most common cause of persistent abnormal LFTs was 
fatty liver (65.4%). Among patients with persistent altered 
LFTs, four patients were hypertensive, three were obese, and 
one patient presented dyslipidemia, while none of them 
had diabetes. In nine patients, cause for persistent LFT 
 abnormalities was not found. One patient had liver metastasis 
at abdominal US examination.
On the other hand, 44 patients had transient abnormal 
LFTs. In this group, 15 patients had drug-induced cholestatic 
liver damage mainly because of immunosuppressants (AZA, 
MTX). Fatty liver, evaluated by US examination, was found 
only in one patient. In the remaining  28  cases, the cause of 
transient abnormal LFTs remained unknown. Six patients 
were hypertensive, three were obese, three had diabetes, and 
other three patients presented dyslipidemia. Seven patients had 
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Table 2. Univariate analysis of risk factors for any abnormal liver function tests.
ABNORMAL LFTs  
(n = 70)




Male 44 (62.9%) 135 (50.9%) 0.08
Female 26 (37.1%) 130 (49.1%)
Mean age (yrs) 48.1 ± 15.0 45.4 ± 15.6 0.2
Duration of disease (months)
1 year 6 (8.6%) 30 (11.3%) 0.6
1–5 years 25 (35.7%) 105 (39.7%)
5 years 39 (55.7%) 130 (49.0%)
IBD type/extent
Crohn’s disease (n = 194)
•	 ileum 10 (23.9%) 40 (26.3%) 0.8
•	 Colon 3 (7.1%) 17 (11.2%)
•	 ileo-colon 26 (61.9%) 84 (55.3%)
•	 Upper gi 3 (7.1%) 11 (7.2%)
Ulcerative colitis (n = 141)
•	 Proctitis 3 (10.7%) 17 (15.1%) 0.04
•	 Left-side colitis 10 (35.7%) 64 (56.6%)
•	 Pancolitis 15 (53.6%) 32 (28.3%)
extra intestinal manifestations 10 (14.3%) 59 (22.2%) 0.18
Previous surgery 15 (21.4%) 48 (18.1%) 0.5
Current smokers 17 (24.3%) 61 (23.0%) 0.7
Medical treatment#
•	 Only aminosalicylates* 16 (22.8%) 97 (36.6%) 0.04
•	 Any corticosteroids** 30 (42.8%) 84 (31.7%) 0.1
•	 Immunosuppressive agents*** 21 (30.0%) 78 (29.4%) 1
•	 TNF-antagonists**** 13 (18.6%) 38 (14.3%) 0.5
Obesity 6 (8.6%) 20 (7.5%) 0.8
diabetes 3 (4.3%) 21 (7.9%) 0.3
Hypertension 10 (14.3%) 37 (13.9%) 0.9
Hypercholesterolemia 4 (5.7%) 26 (9.8%) 0.3
Notes: #Some patients with more than one treatment. *Mesalazine, sulfasalazine; **Includes budesonide, prednisone, methylprednisolone; ***Azathioprine, 
6-mercaptopurine, methotrexate; ****Infliximab, adalimumab.
Abbreviations: LFTs, liver function tests; IBD, inflammatory bowel diseses; GI, gastrointestinal.
also incidental abnormalities at US examination: four benign 
cysts, two angiomas, and one focal  nodular liver hyperplasia.
Among the 70 patients with abnormal LFTs, 28 patients 
(40.0%) had isolated abnormal aminotransferases and were 
considered to have a cytolytic pattern of liver damage. In 
all, 42 patients had also abnormal GGT and ALP levels being 
classified as cholestatic liver damage. A comparison of demo-
graphic and clinical features between the groups with cytolytic 
and cholestatic LFT abnormalities is shown in Table 4. There 
were no significant differences between the two groups with 
regard to gender, IBD subtype, history of intestinal resec-
tion, extra-intestinal manifestation, and smoking. Patients 
with cholestatic pattern of LFT abnormalities were slightly 
older (52.0 ±  15.4  vs.  42.3 ±  14.0  years, P =  0.01) and had 
a longer duration of disease (P =  0.005) than patients with 
cytolytic pattern. The presence of co-existing hypertension 
was  significantly higher in patients with cholestatic pattern 
(P = 0.005).
Discussion
Several series described altered LFTs in IBD patients.3–6,16–24  
The reported prevalence is variable depending on practice 
settings and the criteria used to define abnormal LFTs, 
making a comparison between different studies difficult. 
Most studies are retrospective and lack matched con-
trol groups. Laboratory tests and US have not been used 
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Table 3. Comparison of clinical and demographic characteristics of iBd patients with persistent vs transient abnormal lFts.
PERSISTENT ABNORMAL 
LFTs (n = 26 )
TRANSIENT ABNORMAL 
LFTs (n = 44)
P VALUE
Gender
Male 16 (60%) 28 (63.6%) 1.0
Female 10 (40%) 16 (36.4%)
Mean Age (yrs) 47.5 ± 17.4 49.1 ± 15.3 0.5
Type of IBD (%)
Cd 10 (38.5%) 18 (40.9%) 1.0
UC 16 (61.5%) 26 (59.1%)
Duration of disease (months)
1 year 5 (19.2%) 1 (2.3%) 0.001
1–5 years 14 (53.8%) 11 (25.0%)
5 years 7 (27.0%) 32 (72.7%)
Medical treatment#
•	 Only aminosalicylates* 8 (30.7%) 8 (18.2%) 0.2
•	 Any corticosteroids** 13 (50.0%) 17 (38.6%)
•	 Immunosuppressive agents*** 2 (7.7%) 9 (20.5%)
•	 TNF-antagonists**** 3 (11.6%) 10 (22.7)
Cause of liver injury
•	 Fatty liver 17 (65.4%) 1 (2.3%) 0.001
•	 Drug-induced cholestasis 0 15 (34.1%)
•	 Unknown 9 (34.6%) 28 (63.6%)
Obesity 3 (11.5%) 3 (6.8%) 0.6
diabetes 0 3 (6.8%) 0.3
Hypertension 4 (15.4%) 6 (13.6%) 1.0
Dyslipidemia 1 (3.9%) 3 (6.8%) 1.0
 
 systematically in the diagnostic work-up. The significance of 
either cytolytic or cholestatic pattern elevation in LFTs has 
not been well addressed.
The prevalence of abnormal LFTs in our cohort was   
20.9% in asymptomatic patients, with no previous known 
liver disease or viral-related hepatic damage. This rate is 
similar to that reported in the literature. An epidemiologic 
study conducted in the county of Stockholm, enrolling more 
than  1,000  UC patients followed up for  15  years, reported 
an  11% prevalence of altered LFTs;18  the screening proce-
dure included only biochemical testing. Persistent alterations, 
confirmed by liver morphology, were found by Schrumpf 
et al21  in  3–15% of IBD patients. More recently, Gisbert 
et al3 observed abnormalities in 15% of IBD patients at some 
time during the five years of the study.
Our study did not show any associations of LFT abnor-
malities with clinical and demographic parameters. Our 
patients with LFT alteration were less likely to be on amino-
salicylates. We do not have an explanation for this finding. On 
the other hand, there are reports of hepatotoxicity related to 
aminosalicylates use.25,26
Transient elevations in LFTs returning to normal levels 
within three months were seen in 62.9% of our patients.  Similar 
observations were reported in a large Swedish  follow-up 
study.18 The most frequent cause of transient LFT  alteration 
was DILI (34.1%), possibly linked to an increased and earlier 
use of immunosuppressive agents in the attempt to reduce the 
use of corticosteroids. The incidence of thiopurine-induced 
hepatotoxicity has been variously reported among different 
case series, and the data are sometimes conflicting. Overall, 
the incidence of hepatotoxicity in IBD patients on AZA/ 
6-MP calculated from previous (mainly retrospective) studies 
seems to be only 1–2% per patient and year of treatment, with 
no difference between AZA and 6-MP.10 A favorable evolution 
of LFTs after withdrawal of AZA/6-MP, with liver enzymes 
returning to normal after stopping the medication, has been 
reported.27,28 In our study, all patients in whom AZA/6-MP 
was withdrawn because of hepatotoxicity normalized LFTs 
after treatment was discontinued. Moreover, most of the cases 
of DILI in our IBD patients were mild.
The cause of transient abnormal LFTs was not clear in more 
than half of the patients. Some patients were on  antibiotics; the 
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Table 4. Univariate analysis of risk factors for cytolytic versus cholestatic pattern of abnormal LFTs.






Male 17 (60.7%) 27 (64.3%) 0.8
Female 11 (39.3%) 15 (35.7%)
Mean age (yrs) 42.3 ± 14.0 52.0 ± 15.4 0.01
Duration of disease (months)
1 year 6 (21.4%) 0 0.005
1–5 years 7 (25.0%) 18 (42.9%)
5 years 15 (53.6%) 24 (57.1%)
IBD type
Crohn’s disease 18 (64.3%) 24 (57.1%) 0.5
Ulcerative colitis 19 (35.7%) 18 (42.9%)
extra intestinal manifestations 5 (17.9%) 5 (11.9%) 0.7
Previous surgery 4 (14.3%) 11 (26.2%) 0.2
Current smoker 7 (25.0%) 10 (23.8%) 0.8
Obesity 2 (7.1%) 4 (9.5%) 0.7
diabetes 0 3 (7.1%) 0.1
Hypertension 0 10 (23.8%) 0.005
Hypercholesterolemia 1 (3.6%) 3 (7.1%) 0.5
Abbreviation: IBD, inflammatory bowel diseses.
possibility of antibiotics causing transient elevation could not 
be completely ruled out. However, in most patients antibiotics 
were continued for several months and the LFTs normalized 
when the patients were still on antibiotics. It should be stressed 
that the short period of  observation is a potential drawback of 
our results because the percentage of the established diagnosis 
may have changed as the time passed.
Fatty liver, diagnosed on abdominal US findings, was the 
most frequent cause of persistent altered LFTs in our cohort. 
Bargiggia et al29  evaluated the prevalence of liver enlarge-
ment and steatosis in a large IBD population and found these 
abnormalities in 39% of CD and 35% of UC patients, a 
higher prevalence than among healthy controls. Other stud-
ies have also confirmed that more IBD patients than controls 
have liver steatosis, with percentages ranging from  13% to 
almost 100%.19,20 However, US changes including hepatomeg-
aly or a dysechoic liver echo pattern have also been observed in 
the absence of any LFT abnormalities in about 60% of IBD 
patients.19 The rate of fatty liver in our study is similar to that 
described in the above-mentioned study, but this finding was 
not related to the presence of obesity or dyslipidemia.
Cholelithiasis was frequently found in our series of 
patients with persistent LFT abnormalities, especially in CD 
patients. Comparable findings have also been reported from 
Italian and Swedish studies.29,30 Abnormal bile salt absorp-
tion is proposed to result in an increased incidence of gall-
bladder stones in CD patients ranging from  13  to  34%.29 
On the other hand, the association between cholelithiasis and 
UC is controversial. Only Lorusso et al31 have reported that 
the prevalence of cholelithiasis is higher in UC patients than 
in the general population.
The most frequent pattern of liver damage was cholestatic. 
Univariate analysis suggested a correlation between older age, 
longer duration of disease, co-existing hypertension, and the 
prevalence of this pattern of LFT elevation.
In conclusion our data suggest that even in the absence 
of symptoms, hepatobiliary function should be monitored in 
IBD patients, given the high incidence of LFT abnormali-
ties. Patients on immunosuppressive treatment should be 
more closely monitored. We did not found any risk factor 
related to cytolytic alteration, whereas cholestatic alterations 
seem to increase in presence of co-existent hypertension, 
older age, and longer duration of disease. Moreover, most 
of the cases of abnormal LFTs in IBD patients are mild 
and spontaneously return to normal values in close to 60% 
of patients. These data need to be further explored in larger 
prospective series.
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